biostudies-literatureUnknownMerli MAssociazione italiana contro le leucemie, linfomi e mieloma-Varese OnlusCOVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a meHematological oncologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC9874469biostudies-literatureSARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.PMC9874469Mina RBillio ACavo MTrentin LDerenzini ECilloni DVisco CMassaia MCorradini PGuidetti AMerli FMarchesi FFederici ABMarchetti MMohamed SCoviello ETisi MCCairoli RVisani GBusca AFalini BGentile MDella Porta MGBocchia MBruna RRomano ABertu LGherlinzoni FPagano LArcaini LGalimberti SMerli MFracchiolla NSScattolin ACudillo LMauro FRPassamonti FCattaneo CFerrarini IGambacorti-Passerini CfalseSARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a me2022-01-01T00:00:00Z2022 Oct2025-04-22T06:19:47.179Z2025-04-05T21:40:00.626ZS-EPMC98744693626512810.1002/hon.3092